Nexium News and Research

RSS

Esomeprazole is a proton pump inhibitor (brand names Sompraz, Zoleri, Nexium, Lucen, Esopral; Axagon in Italy, Nexiam in Belgium and South Africa) developed and marketed by AstraZeneca which is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. Esomeprazole is the ''S''-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole. However, this greater efficacy has been disputed, with some claiming it offers no benefit from its older form.

New tool for pharmaceutical industry: VCD from BioTools

Vibrational circular dichroism (VCD), a new tool for determining the absolute configuration of chiral molecules, was a key highlight of the recent 24th International Symposium on Chirality, held June 10-13 in Fort Worth, Texas. VCD pioneer, BioTools (Jupiter, FL) was on hand, not only sponsoring the exhibitor’s luncheon and the poster awards, but also proudly awarding the Best Poster Given by a Young Scientist for the thirteenth year.

12 Jul 2012

Multiple companies receive FDA approval to sell generic Plavix

The U.S. Food and Drug Administration today approved generic versions of the blood thinning drug Plavix (clopidogrel bisulfate), which helps reduce the risk of heart attack and stroke by making it less likely that platelets in the blood will clump and form clots in the arteries.

18 May 2012

FDA may allow many chronic ailment drugs to be available over-the-counter

The U.S. Food and Drug Administration (FDA) is deciding on a proposal to waive prescription requirements for commonly used drugs that treat conditions like diabetes, asthma, and migraines.

11 Mar 2012

IFHP releases 2011 Comparative Price Report

The International Federation of Health Plans today released its 2011 Comparative Price Report detailing its annual survey of medical costs per unit. Designed to showcase the variation in healthcare costs around the world, the report examines the costs of medical procedures, tests, scans and treatments in nine countries.

3 Mar 2012

Acid reducing drugs could raise risk of C. diff diarrhea

U.S. health regulators, the Food and Drugs Administration (FDA), have announced that ulcer drugs such as AstraZeneca Plc's blockbuster Nexium could increase the risk of Clostridium difficile-associated diarrhea (CDAD).

9 Feb 2012

$Heart burn drugs and hip fractures in postmenopausal women smokers: Study establishes link$

Heart burn drugs and hip fractures in postmenopausal women smokers: Study establishes link

A new study shows that postmenopausal women with a history of smoking who take heartburn drugs called proton pump inhibitors (PPIs) for two years or longer may be more likely to sustain a hip fracture. The risk rises with longer use say researchers. But the risk does disappear after women stop taking these drugs for two years. Further women who never smoked were not at increased risk for hip fracture even if they took PPIs regularly, the study showed. The new findings appear in the journal BMJ.

2 Feb 2012

Heartburn drugs ineffective in kids with asthma: Study

A drug used to treat acid reflux has often been used for hard-to-treat asthma. A new study finds that it does not help children with the breathing disease and may cause side effects.

24 Jan 2012

C&EN explains logic behind odd-sounding generic names

Oseltamivir. Esomeprazole. Trastuzumab. Where do drugs get those odd-sounding generic names? The answers are in the current issue of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, the world's largest scientific society, which explains the logic behind the tongue-twisters.

19 Jan 2012

HealthWarehouse.com launches pre-order program for generic Lipitor

HealthWarehouse.com, Inc., a leading VIPPS-accredited, retail mail-order pharmacy, announced today the launch of its pre-order program to enable consumers immediate access to Atorvastatin (Generic Lipitor®) on Dec. 5. HealthWarehouse will offer the medication at up to 50 percent less than the branded versions from retail pharmacies.

29 Nov 2011

First Edition: October 24, 2011

Today's headlines include a variety of health policy news developments, including speculation about how the Supreme Court might review the health law and what's happening with the super committee.

24 Oct 2011

AstraZeneca Canada introduces new NEXIUM Patient Support program

Canadian pharmaceutical company, AstraZeneca Canada Inc., has introduced a new NEXIUM® Patient Support program designed to give physicians and pharmacists the ability to take cost out of the equation in the patient's choice between NEXIUM® tablets and a generic esomeprazole product.

9 Sep 2011

Watson announces acquisition of Specifar Pharmaceuticals

Watson Pharmaceuticals, Inc. and Specifar Pharmaceuticals S.A. today jointly announced that Watson has acquired the privately-held multinational generic pharmaceutical developer, manufacturer and marketer for EUR 400 million in cash and certain contingent consideration.

25 May 2011

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

AstraZeneca announced today that the U.S. Food and Drug Administration has approved the use of NEXIUM I.V. for Injection for children ages greater than 1 month old for the short-term treatment of gastroesophageal reflux disease with erosive esophagitis when oral therapy is not possible or appropriate.

3 May 2011

AstraZeneca introduces new CRESTOR and NEXIUM customer service websites

AstraZeneca announced today the launch of "click-to-chat" on CRESTOR.com and PurplePill.com. The new "click-to-chat" technology gives consumers an option to contact a live AstraZeneca customer service representative with just a click of a button.

28 Apr 2011

America’s best loved drugs: Report

According to the latest report from consulting firm IMS Health, Americans are consuming a lot of prescription drugs. And they seem especially fond of those to lower their cholesterol, relieve heartburn, aid in depressive disorders and lessen pain. Overall, however, their spending on such drugs is slowing.

20 Apr 2011

Broad opportunities for covalent drugs

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the publication of a scientific review article in Nature Reviews Drug Discovery titled "The Resurgence of Covalent Drugs".

1 Apr 2011

Dr. Reddy’s third quarter consolidated revenues increase 10% to $424 million

Dr. Reddy's Laboratories Ltd. today announced its unaudited financial results for the quarter ended December 31st, 2010 under International Financial Reporting Standards (IFRS).

25 Jan 2011

Study on using Public Relations to launch, grow and extend brands throughout a product's lifecycle

Traditionally, Public Relations has served as a limited marketing tool for generating brand awareness and reaching consumers. More recently, the reach and potential of Public Relations has greatly expanded through technologies such as Web sites, online social networks, information alerts and blogs. Meanwhile, traditional media sources continue to play an important role.

25 Nov 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

Firm sees drugs sales rising 5 to 7 percent next year, other drug industry news

The Associated Press reports that global prescription drug sales should rise 5 percent to 7 percent next year reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm IMS Health.

8 Oct 2010